Tirzepatide was noninferior to dulaglutide for the primary endpoint of time to first occurrence of death from cardiovascular causes, myocardial infarction, or stroke. Topline data were announced from ...
Tirzepatide is noninferior to dulaglutide regarding composite of death from CV causes, myocardial infarction, or stroke.
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the ...
Please provide your email address to receive an email when new articles are posted on . Tirzepatide prevented cardiovascular events similarly to dulaglutide in patients with diabetes and heart disease ...
Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial, ...
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the ...
The diabetes drug dulaglutide (Trulicity) may significantly lower a woman’s risk of substantial weight gain after she has given up smoking, finds a secondary analysis of clinical trial data, published ...
Please provide your email address to receive an email when new articles are posted on . Semaglutide is approved by the FDA for slowing the progression of chronic kidney disease. Liraglutide and ...
No significant increase in hazard ratios seen for GI events for semaglutide vs dulaglutide, tirzepatide vs dulaglutide, tirzepatide vs semaglutide. HealthDay News For patients with type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback